Search clinical trials for: FMX101, Minocycline 4% foam

Total 45 results

Vyne Therapeutics Inc.

Completed

A Pharmacokinetic Study of Minocycline in Male and Female Volunteers

Acne

Israel
Vyne Therapeutics Inc.
Premier Research Group plc

Completed

A Study (Study 1) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea

Facial Papulopustular Rosacea

United States
Vyne Therapeutics Inc.
Premier Research Group plc

Completed

A Study (Study 2) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea

Facial Papulopustular Rosacea

United States
Vyne Therapeutics Inc.

Completed

A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne

Acne Vulgaris

United States, Dominican Republic
Vyne Therapeutics Inc.

Completed

A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne

Acne Vulgaris

United States, Dominican Republic
Vyne Therapeutics Inc.

Completed

A Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 in the Treatment of Moderate-to-Severe Acne Vulgaris

Acne Vulgaris

United States
Vyne Therapeutics Inc.

Completed

Safety and Efficacy Study of a Topical Minocycline Foam in Patients With Papulopustular Rosacea (EMIRA)

Rosacea | Papulopustular Rosacea

Germany
Cutia Therapeutics (Shanghai) Co., Ltd

Completed

To Evaluate the Efficacy and Safety of Minocycline Hydrochloride Foam in the Treatment of Moderate-to-severe Acne Vulgaris

Acne Vulgaris

China
Vyne Therapeutics Inc.

Completed

Clinical Study to Evaluate Tolerability and Safety of FXFM244 and to Monitor Clinical Effect in Acne Vulgaris Patients

Acne Vulgaris

Israel
Edward Lain, MD
Vyne Therapeutics Inc.

Completed

A Companion Treatment Study for Patients With Moderate to Severe Acne Vulgaris

Acne Vulgaris

United States
Vyne Therapeutics Inc.

Completed

Dermal Phototoxicity Study

Healthy
Vyne Therapeutics Inc.

Completed

Safety, Tolerability and Efficacy Study of Doxycycline Foam for the Prevention of EGFRI Skin Toxicity in Cancer Patients

Rash Due to Epidermal Growth Factor Receptor Inhibitors

Israel
Vyne Therapeutics Inc.

Terminated

Study to Evaluate the Safety and Efficacy of Topical Minocycline FXFM244 in Rosacea Patients

Rosacea

Israel
Vyne Therapeutics Inc.

Completed

Study to Evaluate the Safety and Efficacy of Topical Minocycline FXFM244 in Impetigo Patients

Impetigo

Israel
Kangabio AUSTRALIA LTD PTY

Not yet recruiting

A Phase 1, First-in-Human of KGX101 to Patients With Advanced or Metastatic Solid Tumors

Advanced or Metastatic Solid Tumors

Australia
Vyne Therapeutics Inc.

Completed

A Study to Compare FCD105 Foam to Minocycline 3% Foam, Adapalene 0.3% Foam and Vehicle Foam.

Acne Vulgaris

United States
Vyne Therapeutics Inc.

Completed

A Study Comparing Two Topicals in the Treatment of Acne Vulgaris

Acne Vulgaris

United States
University of California, San Francisco
National Institute of Neurological Disorders and Stroke (NINDS)

Completed

Tetracycline-Derivatives for Treatment of Cerebral Arteriovenous Malformations and Aneurysms

Arteriovenous Malformations | Aneurysms

United States
Mylan Inc.
Vyne Therapeutics Inc.; DPT Laboratories, Ltd.

Completed

A Dose Ranging Vehicle Controlled Study to Determine the Safety and Efficacy of Permethrin Foam, 5% and Permethrin Foam, 4% for the Treatment of Scabies

Scabies

United States, Dominican Republic, Honduras, Puerto Rico
AstraZeneca
Parexel

Completed

A Study to Assess the Bioavailability of Different Formulations of AZD5718 and the Food Effect on the Selected Formulation of AZD5718 in Healthy Volunteers

Coronary Artery Disease

United Kingdom
M.D. Anderson Cancer Center
American Cancer Society, Inc.

Completed

Phase II Study of Minocycline for Reducing Symptom Burden in Colorectal Patients

Colorectal Cancer

United States
Amarin Pharma Inc.

Completed

Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL) (ANCHOR)

Hypertriglyceridemia

United States
Amarin Pharma Inc.

Completed

Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL (MARINE)

Hypertriglyceridemia

United States, Netherlands, Russian Federation, Ukraine, Denmark, Finland, Germany, India, Italy, Mexico, South Africa
Oystershell NV

Completed

Safety and Efficacy Study to Compare a 4% Dimethicone Foam and Nix Cream Rinse (1% Permethrin) in the Control of Head Lice

Head Lice

United States
Radicle Science

Completed

Radicle Calm 2: A Study of Health and Wellness Products on Feelings of Anxiety, Stress, and Health Outcomes

Stress | Anxiety

United States
Radicle Science

Completed

Radicle Clarity: A Study of Health and Wellness Products on Mental Clarity and Health Outcomes

Cognitive Function

United States
Marmara University

Recruiting

Investigation of the Relationship Between Central Sensitization and Neuropathic Pain in Lumbar Disc Herniation

Central Sensitisation

Turkey
Kavita Sarin
National Institutes of Health (NIH); Medivir; American Skin Association

Completed

Topical Remetinostat in Treating Patient With Cutaneous Basal Cell Cancer

Skin Basal Cell Carcinoma

United States
Bezmialem Vakif University

Completed

Neuropathic Pain in Psoriatic Arthritis

Psoriatic Arthritis

Turkey
Radicle Science

Completed

Radicle Rest 2: A Study of Health and Wellness Products on Sleep and Health Outcomes

Sleep Disorder | Sleep | Sleep Disturbance

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome

Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Allogeneic Hematopoietic Stem Cell Transplantation Recipient

United States
Medical University of Lublin

Completed

Four-arm Mesh for Vaginal Stump Prolapse

Pelvic Organ Prolapse | Sexual Function Abnormal

Poland
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome

Leukemia | Myelodysplastic Syndrome | Recurrent Myelodysplastic Syndrome

United States
British Columbia Cancer Agency
Hoffmann-La Roche

Completed

Systemic and Topical Treatments for Rash Secondary to Erlotinib in Lung Cancer (LUTRAERL)

Rash

Canada
Case Comprehensive Cancer Center

Suspended

Vitamin B12 for Aromatase Inhibitors Associated Musculoskeletal Symptoms in Breast Cancer

HR-positive Breast Cancer

United States
Tourcoing Hospital
Eric SENNEVILLE M.D. Ph.D.

Completed

Tedizolid Prolonged Treatment for Prosthetic Joint Infections (TEDIZOAM)

Prosthetic Joint Infection

France
National Cancer Institute (NCI)

Recruiting

Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene

Malignant Solid Neoplasm

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Reducing Symptom Burden - Non Small Cell Lung Cancer (NSCLC)

Non Small Cell Lung Cancer
Fondazione per la Medicina Personalizzata

Active, not recruiting

The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy (ROME)

Breast Cancer | Non Small Cell Lung Cancer | Gastrointestinal Cancer | Other Cancer

Italy
Southwest Oncology Group
National Cancer Institute (NCI); Roche-Genentech

Completed

S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer

Colorectal Cancer

United States
National Cancer Institute (NCI)

Not yet recruiting

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma

Localized Extraskeletal Ewing Sarcoma | Peripheral Primitive Neuroectodermal Tumor of Bone | Peripheral Primitive Neuroectodermal Tumor of Soft Tissues

United States, Canada, Saudi Arabia, Australia, New Zealand, Puerto Rico
National Cancer Institute (NCI)

Recruiting

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

Neuroblastoma | Ganglioneuroblastoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

Ganglioneuroblastoma | High Risk Neuroblastoma

United States, New Zealand, Australia
National Cancer Institute (NCI)

Active, not recruiting

Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer

PRETEXT I Hepatoblastoma | PRETEXT II Hepatoblastoma | PRETEXT III Hepatoblastoma | PRETEXT IV Hepatoblastoma

United States, Canada, Puerto Rico, Australia, Japan, Brazil

Search clinical trials for: FMX101, Minocycline 4% foam

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Montenegro

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations